Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HB002.1M dose and regimen in diabetic macular edema
CTR20212479Phase 2Active
- Sponsor
- Huabo Biopharm
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HB002.1M in diabetic macular edema (DME), sponsored by Huabo Biopharm. Started Oct 2021; status: active.
02
Drugs
HB002.1M
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20212479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212479.